Pulmonary large cell neuroendocrine carcinoma
MONDO:0003960A large cell neuroendocrine carcinoma that involves the lung(s).
Also known as: LCNEC of the lung, large cell lung carcinoma with neuroendocrine differentiation, large cell lung neuroendocrine carcinoma, large cell neuroendocrine carcinoma of lung, large cell neuroendocrine carcinoma of the lung, lung large cell neuroendocrine carcinoma, pulmonary large cell neuroendocrine carcinoma
2843 clinical trials for this condition and its sub-types, 20 tagged with Pulmonary large cell neuroendocrine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pulmonary large cell neuroendocrine carcinoma
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to tame rare lung cancer
Disease control Not yet recruitingThis study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New radiation drug targets tough cancers in early trial
Disease control Not yet recruitingThis early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Triple-Drug cocktail takes aim at rare, aggressive cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC